Sensorineural Hearing Loss in Seropositive Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder
Table 2
Characteristics of NMOSD or MOGAD patients with SNHL.
Case 1
Case 2
Case 3
Case 4
Case 5
Age
49
70
34
22
57
Sex
F
F
F
F
F
Diagnosis
NMOSD
NMOSD
NMOSD
MOGAD
MOGAD
Location of onset
Brain
Optic neuritis
Myelitis
Optic neuritis
Optic neuritis
Disease duration, years
9
18
19
7
6
History of optic neuritis
+
+
+
+
+
History of myelitis
+
+
+
-
-
Site of HL
Bilateral
Right
Bilateral (more severe on the left)
Right
Right
Time from onset to hearing loss
0.8 years before onset
16 years after onset
8 years after onset
At onset
8 years before onset
Type
SNHL
SNHL+CHL
SNHL
SNHL
SNHL+CHL
Audiometry (Hz)
2000−8000
All
2000−8000
8000
All
Treatment at the time of HL
Steroid
Steroid
Steroid
Steroid
None
Prognosis of HL
Not improved
Not improved
Not improved
Not improved
Not improved
NMOSD: neuromyelitis optica spectrum disorder; MOGAD: myelin oligodendrocyte glycoprotein antibody-associated disease; NA: not available; SNHL: sensorineural hearing loss; CHL: conduction hearing loss. Disease onset was based on the presentation of the first core clinical characteristic with objective clinical evidence.
